Skip to Content
SclerosisSclerosis
  • Review
  • Open Access

13 July 2026

27 Pages

Cerebrovascular Disease in Amyotrophic Lateral Sclerosis: Epidemiology, Mechanisms, and Clinical Implications

,
,
,
,
,
,
,
,
and
1
Department of Medicine, College of Health, Ladoke Akintola University of Technology, Ogbomoso 210214, Nigeria
2
Department of Public Health, Ahmadu Bello University, Zaria 810001, Nigeria
3
Department of Medicine, LAUTECH Teaching Hospital, Ogbomoso 210214, Nigeria
4
Department of Medicine, University of Ilorin Teaching Hospital, Ilorin 210003, Nigeria

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease primarily affecting upper and lower motor neurons. Although cerebrovascular disease (CVD) and ALS have traditionally been studied as distinct entities, a growing body of evidence indicates meaningful epidemiological, pathophysiological, and clinical overlap between the two conditions. This narrative review synthesizes current evidence on the coexistence of ALS and cerebrovascular disease, examines shared mechanistic pathways, addresses diagnostic challenges, including stroke mimicry, considers clinical management implications, and identifies priorities for future research. A search of PubMed, Scopus, Web of Science, and EMBASE was conducted through February 2026 using the terms “amyotrophic lateral sclerosis,” “motor neuron disease,” “cerebrovascular disease,” “stroke,” “ischemic stroke,” “blood-brain barrier,” “neuroinflammation,” and “neurovascular coupling,” alone and in combination. Peer-reviewed original research, systematic reviews, meta-analyses, population-based studies, registry analyses, and expert consensus statements were included. Studies were assessed for methodological quality and relevance to the review objectives. This review is reported as a narrative synthesis. Population-based data demonstrate a bidirectional relationship between ALS and cerebrovascular events. ALS patients face an approximately 2.6-fold elevated risk of ischemic stroke, and prior cerebrovascular injury modestly increases subsequent ALS risk. Shared pathophysiological mechanisms include neuroinflammation with microglial M1/M2 polarization imbalance, pro-inflammatory cytokine cascades mediated via NF-κB signaling, oxidative stress and SOD1 pathway dysregulation, glutamate excitotoxicity, blood–brain barrier (BBB) dysfunction, and impaired neurovascular coupling. Diagnostic confusion arises because upper motor neuron–predominant ALS can closely mimic acute ischemic stroke. Concurrent cerebrovascular disease appears to accelerate functional decline and reduce survival in ALS. Resource-limited settings face compounded challenges from diagnostic misclassification, restricted EMG access, and limited specialist availability. The ALS–cerebrovascular overlap is clinically relevant, biologically plausible, and systematically understudied. Integrated multidisciplinary management, prospective longitudinal cohort studies, and linked registry analyses are urgently needed to clarify causal relationships, characterize shared disease mechanisms, and improve patient outcomes.

1. Introduction

Amyotrophic lateral sclerosis (ALS), historically known as Lou Gehrig’s disease, is a relentlessly progressive neurodegenerative disorder characterized by the selective degeneration and death of both upper motor neurons (UMNs) in the motor cortex and lower motor neurons (LMNs) in the brainstem and spinal cord [1]. The loss of these neurons disrupts the efferent pathways required for voluntary movement, producing progressive muscle weakness, wasting, spasticity, and ultimately respiratory failure. Four principal clinical phenotypes are recognized: limb-onset ALS, with mixed UMN and LMN signs; bulbar-onset ALS, which begins with dysarthria and dysphagia before spreading to limb musculature; primary lateral sclerosis, confined to UMN involvement; and progressive muscular atrophy, predominantly affecting LMNs. Median survival from symptom onset is typically 2–5 years, though considerable variability exists depending on the site of onset, progression rate, and the presence of cognitive comorbidities [2].
ALS is etiologically multifactorial, involving an interplay of genetic susceptibility and environmental exposures. Approximately 90–95% of cases are sporadic (sALS), while 5–10% are familial (fALS) with identifiable Mendelian inheritance. The most clinically significant disease genes are C9orf72 (accounting for ~40% of fALS and ~5–8% of sALS), SOD1 (~20% of fALS), TARDBP (encoding TDP-43, ~5% of fALS), and FUS (~5% of fALS), collectively representing approximately 70% of all familial cases [1]. Pathologically, phosphorylated 43 kDa TDP-43 protein (pTDP-43) accumulates in the cytoplasm of neurons and glial cells in approximately 97% of ALS cases, making it the most prevalent pathological hallmark of the disease [2].
ALS is increasingly recognized as a multisystemic disease. Beyond the defining motor neuron degeneration, recent studies demonstrate that non-motor features, including neuropsychiatric symptoms, cognitive impairment (including ALS-frontotemporal dementia spectrum, ALS-FTD), autonomic dysregulation, vascular disturbances, sleep disorders, and gastrointestinal dysfunction, are frequent and clinically significant. These non-motor manifestations increase morbidity, impair quality of life, and complicate clinical management [2,3].
Cerebrovascular disease constitutes the leading cause of adult disability worldwide and the second leading cause of death globally, with stroke accounting for approximately 12.2 million incident cases annually [4]. In the United States, stroke is the leading cause of adult long-term disability and a leading contributor to dementia. Despite their distinct etiologies, ALS and cerebrovascular disease share several biological features, including motor pathway involvement, excitotoxic injury, neuroinflammation, and overlapping clinical presentations that render the differential diagnosis and the clinical management of coexisting disease particularly challenging.
This review examines the intersection of ALS and cerebrovascular disease across four domains: (1) the epidemiology of their co-occurrence; (2) shared risk factors and pathophysiological mechanisms; (3) diagnostic challenges arising from stroke mimicry; (4) prognostic and clinical management implications; and (5) the particular challenges faced in low- and middle-income country (LMIC) settings. We conclude with a forward-looking research agenda targeted at resolving key unanswered questions.

2. Methods

This review was conducted as a narrative synthesis of the published literature on the intersection of amyotrophic lateral sclerosis and cerebrovascular disease. A systematic search of four major electronic databases, PubMed, Scopus, Web of Science, and EMBASE, was performed, with coverage extending through February 2026. The search was constructed using the following terms, applied individually and in Boolean combination: “amyotrophic lateral sclerosis,” “motor neuron disease,” “cerebrovascular disease,” “stroke,” “ischemic stroke,” “blood-brain barrier,” “neuroinflammation,” and “neurovascular coupling.” No language or date restrictions were imposed at the search stage.
Eligible publications included peer-reviewed original research articles, systematic reviews, meta-analyses, population-based cohort studies, national and regional registry analyses, and expert consensus statements. Case reports and conference abstracts were considered only where they provided unique mechanistic or clinical data not available in full-length publications. Studies were included if they addressed at least one of the following domains: (1) the epidemiology of ALS and cerebrovascular disease co-occurrence; (2) shared pathophysiological mechanisms; (3) diagnostic overlap or stroke mimicry; (4) prognostic interactions; or (5) management challenges in resource-limited settings.
All retrieved records were assessed for methodological quality and relevance to the review objectives. For epidemiological studies, particular attention was paid to sample size, comparator group selection, adjustment for confounding variables, and the use of validated diagnostic codes or clinical ascertainment. For mechanistic studies, consideration was given to whether findings were derived from human tissue, animal models, or in vitro systems, and results were contextualized accordingly. Studies relying exclusively on administrative coding without clinical validation were noted as a potential source of misclassification bias.
Data were synthesized narratively, with evidence organized thematically across the five domains outlined above. Given the heterogeneity of study designs, populations, and outcome definitions across the retrieved literature, formal meta-analytic pooling was not performed. Where quantitative estimates were available from multiple studies addressing the same question, such as the relative risk of ischemic stroke in ALS patients, findings are presented in a comparative summary. This review is reported in accordance with the principles of the Scale for the Assessment of Narrative Review Articles (SANRA) framework for narrative reviews.

3. Epidemiology of Cerebrovascular Disease in ALS

Dedicated epidemiological studies examining the co-occurrence of ALS and cerebrovascular disease are limited, but converging data from national registries and population-based cohorts consistently indicate an elevated cerebrovascular burden among ALS patients. The most direct evidence comes from a nationwide cohort study using the South Korean National Health Insurance Service database, which demonstrated that ALS patients had a significantly higher incidence of ischemic stroke compared with age- and sex-matched controls, with an event rate of approximately 7.3 per 1000 person-years and an adjusted hazard ratio of 2.58 (95% CI 1.38–4.82) [5]. This represents a more than twofold excess risk, even after adjustment for standard vascular risk factors.
Evidence also supports a bidirectional relationship [6]. A population-based record-linkage analysis from England demonstrated that prior cerebrovascular injury was associated with a modestly increased risk of subsequently developing ALS, with rate ratios of 1.38 following ischemic stroke and 1.47 following transient ischemic attack (TIA) [7]. These findings suggest that vascular injury may directly lower the threshold for motor neuron degeneration through shared pathological mechanisms or may unmask subclinical ALS in susceptible individuals, a hypothesis consistent with a “multiple-hit” model of ALS pathogenesis.
The burden of ALS itself is growing. The National ALS Registry projected approximately 32,893 prevalent ALS cases in the United States in 2022, with a projected 10% increase to 36,308 cases by 2030 [8]. This demographic shift is substantially driven by population aging, with an estimated 25% increase in ALS prevalence attributable to the growing proportion of older adults [9]. Given that advanced age is the single greatest shared risk factor for both ALS and stroke, these parallel trends predict an increasing convergence of the two conditions within healthcare systems over the coming decade.
Paradoxically, several European and North American cohort studies have found lower prevalence of traditional cardiovascular risk factors, including hypertension, diabetes, and obesity, among ALS patients compared with both the general population and neurological disease controls [10,11,12]. This phenomenon, termed “reverse epidemiology,” suggests that ALS may involve an atypical systemic metabolic profile in which standard vascular risk factors associate inversely with disease risk, possibly reflecting a pre-morbid biological landscape of heightened metabolic efficiency or constitutional fitness that paradoxically predisposes to motor neuron degeneration.
Despite the apparent reduction in traditional risk factors, vascular comorbidity materially influences ALS survival. National ALS Registry data indicate that while respiratory failure remains the leading cause of death, cardiovascular disease and cardiac arrest are frequently listed as contributing causes of mortality [13]. In the Catalan ALS registry, the median survival from diagnosis was approximately 2.19 years, and patients with a prior history of stroke demonstrated significantly shorter survival times [14]. Similar patterns are observed in European registries where cardiovascular causes represent primary terminal events in a subset of patients who do not succumb to respiratory failure [9]. Long-survivors of ALS, often characterized by younger age at onset and spinal-onset phenotypes, become increasingly susceptible to cerebrovascular events as they age with the disease, highlighting the need for sustained vascular surveillance in this group [15].
Significant gaps persist in the epidemiology of ALS-related cerebrovascular disease. Most available datasets rely on administrative coding, limiting granularity regarding stroke subtype, vascular mechanism, and lesion severity. The overwhelming majority of published data derive from European and North American populations. Data on hemorrhagic stroke, TIA, and subclinical cerebrovascular disease in ALS are virtually absent. Stroke risk has not been systematically characterized by ALS phenotype (bulbar vs. spinal, UMN vs. LMN predominant) or rate of disease progression. Addressing these gaps requires large-scale, prospectively designed studies with rigorous vascular phenotyping in ALS populations.

4. Shared Risk Factors and Converging Mechanisms

4.1. Age

Age is the most important non-modifiable shared risk factor for both ALS and cerebrovascular disease. The peak incidence of ALS occurs between the ages of 55 and 75 years, and advanced age is the single strongest predictor of ischemic stroke [4,16]. In the South Korean nationwide cohort study, the mean age of ALS participants was approximately 61 years, and stroke risk did not differ significantly between ALS patients with and without significant functional disability, suggesting that age-related neurobiological vulnerability rather than disability per se drives the elevated cerebrovascular risk [6]. In a Swedish population-based case–control study by Chourpiliadis et al., the association between cerebrovascular disease and ALS risk was strongest among patients aged 67 years or older at diagnosis, reinforcing age as a modifying variable in the ALS-CVD relationship [17].

4.2. Smoking

Cigarette smoking is one of the most important modifiable shared risk factors. Epidemiologically, smoking increases the risk of coronary heart disease by approximately 30% and stroke incidence by 20–30% [4]. In the context of ALS, a pooled analysis of five prospective cohorts (n = 1,153,435) found that smoking was associated with a significant increase in ALS risk, with a 9% increase per 10 cigarettes smoked per day, and with risk increasing with earlier age of smoking initiation (p = 0.028) [18]. Formaldehyde, a toxic combustion by-product of cigarette smoke, has been estimated to increase ALS risk by approximately 34%, potentially through protein crosslinking and motor neuron oxidative injury [19]. Although no study has directly examined the incremental contribution of smoking to cerebrovascular risk specifically within ALS populations, its dual contribution to both conditions underscores its importance as a modifiable target for risk reduction.

4.3. Metabolic and Lipid Factors

Shared metabolic disturbances may provide mechanistic links between ALS and cerebrovascular disease. Cerebral ischemia has been shown to induce aggregation of neurodegenerative proteins, including TDP-43 and FUS, within neuronal tissue, suggesting that vascular injury may initiate or amplify proteinopathy cascades relevant to ALS [20]. Shared hypoxia-response pathway dysregulation, particularly involving HIF-1α and its downstream mediators VEGF and VEGFR, occurs in both ischemic stroke and ALS, pointing to a common vascular stress response that may contribute to neuronal vulnerability in both conditions [21].
Lipid metabolism disturbances are increasingly implicated in ALS pathogenesis and may also modulate cerebrovascular risk. A recent longitudinal metabolomic study demonstrated impaired carnitine and short-chain acylcarnitine metabolism in ALS patients over time, suggesting genetically determined disruption of lipid oxidation pathways [22]. Multiple lipid classes, including primary fatty acids and sphingolipids, are independently associated with both severity and rate of functional decline in ALS [23]. Higher plasma HDL cholesterol and apolipoprotein A1 concentrations are associated with reduced ALS risk [24], whereas a large Norwegian cohort study (n = 425,564; 16-year follow-up) demonstrated that statin initiation within one year before ALS diagnosis was strongly associated with pre-existing lipid abnormalities, and that long-term statin use correlated with reduced ALS risk in men a finding consistent with a pathogenic role for dyslipidemia in the pre-clinical phase [25].
At the blood–brain barrier level, oxysterol accumulation arising from cholesterol oxidation under conditions of oxidative stress has been shown to damage the BBB and blood–spinal cord barrier (BSCB) in both ALS transgenic mouse models and postmortem human tissue. Postmortem studies have demonstrated endothelial cell injury, severe intra- and extracellular edema, perivascular collagen IV deposition, and reduced tight junction protein expression in ALS tissue [26,27]. These findings indicate a BBB phenotype shared with chronic cerebrovascular disease and suggest that lipid-mediated vascular injury may represent a convergence point between the two conditions.

4.4. Physical Activity and Immobility

The relationship between physical activity and ALS risk is paradoxical. Studies including Mattsson et al. and Turner et al. report that higher levels of premorbid cardiovascular fitness and physical activity are paradoxically associated with ALS risk [28,29], though this finding is inconsistent across studies [30]. This “athletic hypothesis” of ALS suggests that repeated microtrauma, oxidative stress from intense exercise, or selection bias for physically active individuals who survive long enough to develop ALS may partly explain the observation. In contrast, ALS-related immobility significantly elevates venous thromboembolism (VTE) risk, which is itself a recognized source of paradoxical cardioembolic stroke and is associated with mortality in ALS [31]. Current evidence does not establish that ALS-related physical disability independently increases ischemic stroke risk [6].

4.5. Malnutrition and Cachexia

Malnutrition is a clinically important and frequently underappreciated complication of ALS, present in up to 20% of patients across published cohorts [32]. It arises from the combined effects of dysphagia, hypermetabolism, increased energy expenditure from respiratory muscle use, and reduced physical activity. Malnutrition is an independent predictor of shorter survival in ALS, with low body mass index and weight loss both conferring poor prognosis. Frailty markers, including slow gait speed, exhaustion, and low grip strength, are similarly associated with increased ALS risk in population studies [33]. Poor nutritional status also adversely affects stroke recovery, rehabilitation capacity, and secondary prevention. No studies have directly assessed the interaction between malnutrition and cerebrovascular outcomes in patients with concurrent ALS and CVD, representing a significant and clinically meaningful knowledge gap.

4.6. Autonomic Dysfunction

Autonomic dysfunction is a recognized but under-characterized feature of both ALS and cerebrovascular disease, and its presence may amplify cardiocerebrovascular risk in both conditions. In stroke, autonomic dysregulation manifests as stroke–heart syndrome, including cardiac arrhythmias, left ventricular dysfunction, QT prolongation, and elevated catecholamine release, as well as endothelial dysfunction and post-stroke hyperglycemia [34]. In ALS, autonomic impairment is most pronounced in bulbar-onset phenotypes and includes cardiovascular features (elevated resting heart rate, blood pressure lability), sudomotor abnormalities, erectile dysfunction, and impaired respiratory autonomic reflexes [35,36].
The neurogenic cardiomyopathy (Takotsubo syndrome) that occurs in 0.5–1.2% of acute ischemic stroke patients and 5–10% of subarachnoid hemorrhage patients [37,38] provides a striking example of brain–heart interaction in cerebrovascular disease. At least five cases of Takotsubo cardiomyopathy have been reported in ALS patients, likely representing an undercount given the rarity of recognition [39]. The shared involvement of hypothalamic and brainstem autonomic centers in both conditions provides a plausible neuroanatomical basis for these observations and warrants systematic investigation (Table 1).
Table 1. Shared Vascular Risk Factors in ALS and Cerebrovascular Disease.
The co-occurrence of ALS and cerebrovascular disease is not merely coincidental at the molecular level either. Multiple micro-level molecular and cellular mechanisms are shared between the two conditions, suggesting that macro-level exposures and micro-level effectors potentiate each other through common biological pathways rather than operating as artificially separable categories. The remainder of this section reviews seven key areas of pathophysiological convergence: neuroinflammation, oxidative stress, glutamate excitotoxicity, blood–brain barrier dysfunction, endothelial dysfunction with impaired neurovascular coupling, the C9orf72-related vascular phenotype, and TDP-43-mediated vascular injury.

4.7. Neuroinflammation

Neuroinflammation is a core pathological feature of both ALS and cerebrovascular disease. It is orchestrated primarily by microglia and infiltrating peripheral lymphocytes, which release a repertoire of pro-inflammatory cytokines, chemokines, and reactive oxygen species [41,42,43].
Preclinical studies in transgenic rodent models of ALS, corroborated by clinical analyses of CSF and blood from fALS and sALS patients, demonstrate that neuroinflammation and immune dysregulation are integral to ALS pathogenesis, phenotypic expression, and disease progression [40]. Systemic inflammation-sensitive biomarkers, including erythrocyte sedimentation rate, C-reactive protein, and fibrinogen, are significantly elevated in ALS patients compared with controls, and their concentrations correlate with disease severity, disability status, and prognosis, suggesting that systemic immune activation is a consistent feature of ALS rather than an epiphenomenon [44,45].

4.7.1. Microglial Activation

Microglia, constituting approximately 10–15% of all CNS cells, are the primary resident immune sentinels of the brain and spinal cord. They originate embryonically from primitive macrophages of the yolk sac [46,47] and maintain CNS homeostasis by monitoring synaptic activity, pruning excess synaptic connections during development, and responding to injury or pathological stimuli [48].
During neuroinflammation, microglia transition from their resting, highly ramified morphology characterized by long, motile processes that continuously survey the parenchyma to an activated amoeboid form that facilitates phagocytosis and amplifies inflammatory signaling [49]. Microglial activation is broadly categorized into classical (M1) and alternative (M2) states, though in vivo activation spectra are more complex and dynamic. M1 activation is characterized by the release of TNF-α, IL-6, IL-1β, IL-12, CCL2, NADPH oxidase-derived reactive oxygen species (ROS), and nitric oxide (NO), and upregulation of MHC class II molecules required for T-lymphocyte antigen presentation [50]. M2 activation, stimulated by IL-4, IL-13, and IL-10, promotes anti-inflammatory and tissue-repair responses through transcription factors, including PPARγ, LXR, and RXR [51].
In ALS, evidence from both animal models and human postmortem tissue demonstrates progressive M1 microglial predominance with failure of transition to reparative M2 states. This sustained pro-inflammatory microglial activation contributes to motor neuron injury through cytotoxic cytokine release, complement activation, and direct phagocytic destruction of stressed but viable motor neurons. In cerebrovascular disease, microglial activation following ischemia likewise progresses from initial M2-mediated neuroprotection to M1-dominated chronic neuroinflammation in the peri-infarct zone, contributing to progressive secondary neuronal loss [41,50].

4.7.2. Cytokine Cascades

Circulating and CNS-compartment pro-inflammatory cytokines are systematically elevated in ALS. A meta-analysis of peripheral blood studies reported significantly increased levels of TNF-α, IL-6, IL-1β, and IL-8 in ALS patients compared with healthy controls [52]—findings consistent with a sustained systemic inflammatory response that extends beyond the CNS. These cytokines are not merely markers of disease activity; they actively modulate endothelial function by activating NF-κB-dependent transcriptional programs that increase oxidative stress, enhance leukocyte adhesion molecule expression, and promote BBB permeability [53,54].
The cytokine amplification cascade operates through an IL-1β/TNF-α → IL-6 loop that sustains inflammatory activity in both neural and vascular compartments. IL-6 drives acute-phase protein production, including C-reactive protein and fibrinogen, which creates a pro-thrombotic, pro-atherogenic state. Downstream, cytokine-mediated NF-κB activation stimulates smooth muscle cell proliferation, matrix metalloproteinase (MMP) expression, and extracellular matrix degradation, contributing to structural vascular remodeling and increased endothelial permeability [53,55,56].

4.7.3. Chronic Inflammatory State and Vascular Consequences

The chronicity of neuroinflammation in ALS is reinforced by persistently elevated cytokine levels and sustained NF-κB pathway activation, both of which have been independently associated with neurovascular injury and disruption of vascular homeostasis in multiple neurodegenerative conditions [53,55]. Inflammatory mediators disrupt claudin-5, occludin, and ZO-1 tight junction proteins within cerebral and spinal endothelial cells, dramatically increasing paracellular permeability and facilitating peripheral immune cell infiltration into neural tissue [54,57]. This neuroinflammatory milieu likely contributes to the increased incidence of cerebrovascular events observed in ALS epidemiological studies by accelerating endothelial dysfunction and promoting a pro-thrombotic vascular state [5,7].

4.8. Oxidative Stress

Oxidative stress is a central and well-established mechanism of motor neuron injury in ALS and plays an equally critical role in ischemic and hemorrhagic cerebrovascular disease. The brain is uniquely vulnerable to oxidative damage owing to its high metabolic rate and oxygen consumption, relatively limited endogenous antioxidant capacity, and the abundance of oxidizable polyunsaturated fatty acids in neuronal membranes [58,59,60].

4.8.1. Mitochondrial Dysfunction

Neuronal mitochondria fulfill dual roles as the primary source of cellular ATP and as critical regulators of intracellular calcium homeostasis. In ALS, mitochondrial dysfunction is an early and consistent pathological finding, preceding overt motor neuron loss in preclinical models [61,62]. In ischemic stroke, energy failure from abrupt cessation of cerebral blood flow disrupts mitochondrial membrane potential within minutes, triggering mass calcium influx and mitochondrial permeability transition pore opening, with ROS overproduction amplifying injury in reperfusion.

4.8.2. SOD1 Pathway Dysregulation

Superoxide dismutase 1 (SOD1) is the principal cytosolic antioxidant enzyme responsible for catalyzing the conversion of superoxide to molecular oxygen and hydrogen peroxide. Mutations in the SOD1 gene, the first identified genetic cause of familial ALS accounting for approximately 20% of fALS cases [63,64,65], produce toxic gain-of-function effects through several intersecting mechanisms: protein misfolding and aggregation, impaired proteasomal degradation, aberrant protein–protein interactions, and mitochondrial dysfunction. Misfolded SOD1 accumulates on the outer mitochondrial membrane and directly inhibits voltage-dependent anion channels (VDAC), impairing adenine nucleotide conductance and bioenergetics [66]. SOD1 aggregates further promote Bcl-2 conformational change to pro-apoptotic forms [67], enhance TDP-43 and FUS aggregation [1], and generate early vascular changes prior to overt motor neuron degeneration in transgenic models [68]. A Drosophila study expressing human A4V and G85R SOD1 mutations confirmed that these variants induce early neuroinflammatory markers and chromosome aberrations, reinforcing the upstream vascular and inflammatory roles of SOD1 dysfunction [69].

4.9. Glutamate Excitotoxicity

Glutamate excitotoxicity neuronal degeneration resulting from excessive stimulation of ionotropic glutamate receptors, particularly N-methyl-D-aspartate receptors (NMDARs), represents one of the three major pathophysiological mechanisms of motor neuron injury in ALS and the therapeutic rationale for riluzole, the first disease-modifying treatment approved for ALS [70,71].
Under physiological conditions, synaptically released glutamate activates synaptic NMDARs (sNMDARs) to mediate normal excitatory neurotransmission. In ALS, impaired astrocytic glutamate reuptake, particularly through reduced expression of the EAAT2/GLT-1 transporter, leads to glutamate accumulation in the synaptic cleft, progressively activating extra-synaptic NMDARs (eNMDARs). Extra-synaptic NMDAR activation triggers cell death signaling, partly mediated through TRPM4 channel coupling [72], resulting in sustained calcium influx, mitochondrial calcium overload, ROS generation, and activation of calcium-dependent proteases and endonucleases [73].
In ischemic stroke, which accounts for approximately 87% of all stroke events globally [74], abrupt reduction in cerebral blood flow produces ATP depletion and failure of Na+/K+-ATPase, Na+/Ca2+ exchange, and plasma membrane Ca2+-ATPase. The resultant intracellular sodium and calcium overload triggers massive, synchronous glutamate release from depolarized neurons and glial cells, overwhelming reuptake mechanisms and producing the characteristic ischemic glutamate storm [75,76,77,78]. Riluzole has shown neuroprotective effects in both ALS and experimental stroke models, further reinforcing the mechanistic convergence and suggesting potential therapeutic translatability across the two conditions.

4.10. Blood–Brain Barrier Dysfunction

4.10.1. Evidence in ALS

Substantial and converging evidence implicates dysfunction of the blood–brain barrier (BBB) and blood–spinal cord barrier (BSCB) as early and active contributors to ALS pathogenesis rather than mere downstream consequences of motor neuron death. In SOD1-linked experimental ALS models, barrier leakage of Evans Blue dye, IgG, and hemosiderin is accompanied by a marked reduction in tight junction proteins ZO-1 and occludin [79]. Parallel vascular alterations, including endothelial degeneration and perivascular protein deposition, have been corroborated in human ALS postmortem tissue, supporting the translational relevance of animal model findings [55,80].
Clinically, elevated CSF total protein, IgG index, and albumin quotient (QAlb) are detected in subsets of ALS patients, with higher barrier-disruption markers correlating with worse prognosis and with ALS-FTD phenotypes [81]. Critically, imaging studies in SOD1G93A mice using radiotracer methods detect BBB hyperpermeability signals that parallel mitochondrial dysfunction and precede overt motor neuron degeneration [82], suggesting that vascular impairment may be an early pathological event in at least some ALS subtypes.
Multiple intersecting mechanisms drive BBB disruption in ALS. Pro-inflammatory cytokines (TNF-α, IL-6) activate microglia and astrocytes through NF-κB-dependent pathways, upregulating endothelial adhesion molecules and oxidative stress pathways that degrade tight junction proteins [53,55]. Endothelial TDP-43 pathology provides an additional mechanism, with loss of endothelial TDP-43 demonstrated to directly impair BBB integrity in mouse models of ALS and FTD [83]. Efflux transporter remodeling alters drug transport dynamics across the BBB, with implications for pharmacotherapy delivery in ALS [84].

4.10.2. Established Role in Stroke

The BBB is a highly dynamic, actively regulated component of the neurovascular unit (NVU), in which endothelial cells, pericytes, astrocytic end-feet, and neuronal signaling cooperate to maintain CNS homeostasis [85]. In ischemic stroke, BBB dysfunction begins within 30–60 min of vessel occlusion through transcellular pathways involving caveolae-mediated transcytosis and progresses to paracellular leakage through tight junction disruption within hours [86,87]. This bidirectional sequence of BBB injury contributes to vasogenic edema formation, neuroinflammatory cascades, hemorrhagic transformation, and progressive secondary neuronal injury [88]. Systemic factors further modulate BBB vulnerability: chronic alcohol exposure induces oxidative stress-mediated tight junction disruption [54], and gut microbiome-derived signals can modulate BBB permeability through immune-mediated pathways [89], factors that may be relevant in ALS patients with gastrointestinal dysfunction and dysbiosis.
Together, these findings position BBB dysfunction not as a passive biomarker but as an active disease modifier in both ALS and cerebrovascular disease. Whether BBB-targeted interventions can be translated into clinical benefit for either or both conditions remains an important unanswered research question.

4.11. Endothelial Dysfunction and Neurovascular Coupling

4.11.1. Hypoxia Signaling and Vascular Regulation Abnormalities

Impaired hypoxia-response signaling represents an important and under-investigated mechanism of vascular dysfunction in ALS. Under conditions of physiological hypoxia, hypoxia-inducible factor-1α (HIF-1α) translocates to the nucleus and drives transcription of adaptive genes including VEGF, EPO, and glucose transporters. In ALS, this adaptive response appears impaired at multiple levels: Nagara et al. (2013) demonstrated markedly reduced cytoplasmic HIF-1α immunoreactivity in anterior horn cells from ALS patients compared with controls (p < 0.0001), accompanied by reduced VEGF, VEGFR-1, and VEGFR-2 expression [90]. Simultaneously, circulating monocytes from sporadic ALS patients show deregulated HIF-1α and VEGF responses under hypoxic conditions, linked to reduced prolyl hydroxylase-2 (PHD-2)-mediated HIF-1α proteolysis [91], indicating that the hypoxia-response defect extends systemically beyond the CNS.
The hemodynamic implications of these findings are significant. Arhart (2010) proposed that impaired cerebral blood flow autoregulation could create chronic regional hypoperfusion in metabolically demanding motor cortex regions, producing sustained metabolic stress and neuronal vulnerability that may contribute to motor neuron degeneration [92]. This hemodynamic hypothesis, while not yet experimentally confirmed, provides a physiologically coherent framework in which endothelial dysfunction and impaired vascular adaptive capacity contribute upstream to motor neuron vulnerability in ALS.

4.11.2. Neurovascular Coupling Impairment

Neurovascular coupling (NVC) is a fundamental mechanism of cerebrovascular regulation whose disruption has been increasingly recognized in both ALS and stroke. In ALS, pathological TDP-43 accumulation may impair microvascular integrity by activating pericytes and astrocytes, inducing neuroinflammation and local BBB leakage [93]. The neuropathological continuum between ALS and FTD through overlapping TDP-43 proteinopathy [94] further raises the possibility that NVC disruption may contribute to the cognitive impairment observed in ALS-FTD. Consistent with these mechanisms, post-stroke cytoplasmic TDP-43 deregulation is associated with microglial activation and NF-κB-mediated neuronal death [95], suggesting that TDP-43 dysregulation may represent a shared response to both neurodegenerative and ischemic insults.
Clinical evidence for NVC impairment in ALS comes from a fMRI study by Trojsi et al. (2025), which demonstrated significantly reduced NVC metrics in 48 ALS patients, with individual NVC reductions correlating with impairment of executive function, memory, and visuospatial ability [96]. In ischemic stroke, acute-phase NVC impairment involves pericyte contraction and loss, endothelial MMP-mediated tight junction degradation, and GFAP/vimentin/S100B-positive astrocyte reactivity [97]. Chronic post-stroke BBB disruption substantially impairs neuroplasticity and is strongly associated with vascular cognitive impairment and post-stroke dementia [98,99]. The mechanistic parallels between pericyte loss, astrocyte reactivity, neuroinflammation, and BBB breakdown across ALS and ischemic stroke in the context of NVC impairment represent a compelling and clinically underexplored convergence point that warrants systematic investigation in patients with concurrent disease.

4.12. C9orf72 Repeat Expansion and the Vascular Phenotype

As the most frequent genetic cause of ALS, accounting for approximately 40% of familial and 5–8% of sporadic cases [100], hexanucleotide repeat expansions in C9orf72 warrant explicit consideration within the vascular framework of this review. Emerging evidence indicates that this mutation produces a cell-autonomous endothelial phenotype that may directly contribute to the cerebrovascular burden observed in carriers [101].
Patient-derived brain microvascular endothelial-like cells generated from C9orf72-ALS patients display altered gene expression profiles, compromised barrier integrity, and increased P-glycoprotein efflux transporter activity relative to control-derived lines [101]. Because this barrier-leak phenotype is reproduced in isolated endothelial cultures lacking neuronal or glial input, it appears to arise through a cell-autonomous mechanism intrinsic to the endothelium itself, rather than being a secondary consequence of neurodegeneration [101]. This finding complements the SOD1- and TDP-43-mediated BBB mechanisms discussed above (Section 4.10 and Section 4.13) and suggests that, in C9orf72 carriers, vascular dysfunction may arise through a genotype-specific pathway operating in parallel with, rather than solely downstream of, motor neuron injury.
Clinically, C9orf72 repeat expansion carriers display remarkably heterogeneous phenotypic and pathological characteristics, spanning pure ALS, ALS-FTD overlap, and pure FTD presentations within the same kindred, alongside variable rates of cognitive decline and survival [102,103]. Whether this heterogeneity is partly attributable to variability in the severity of the underlying vascular phenotype, rather than being driven exclusively by differences in TDP-43 burden or repeat length, has not been systematically investigated and represents a plausible explanation deserving dedicated study. Given the size of the C9orf72-ALS subgroup, characterizing BBB integrity and cerebrovascular risk specifically within repeat-expansion carriers, rather than ALS cohorts as a whole, may help resolve some of the unexplained variance in the ALS–cerebrovascular relationship described in Section 3.

4.13. TDP-43 Pathology and Vascular Injury

As the most prevalent pathological hallmark of ALS, present in approximately 97% of cases, TDP-43 proteinopathy merits a more direct examination of its vascular consequences than the brief treatment in Section 4.11.2 above provides. Four converging lines of evidence implicate TDP-43 as an active participant in vascular injury rather than a purely neuronal phenomenon.
Regarding endothelial TDP-43 and barrier integrity, nuclear TDP-43 expression is reduced in capillary endothelial cells of patients along the ALS-FTD spectrum, and conditional loss of endothelial TDP-43 in mouse models is sufficient to produce BBB defects in the absence of any neuronal TDP-43 pathology [104]. This endothelial-intrinsic mechanism parallels the C9orf72 findings described in Section 4.12 and suggests that barrier dysfunction in ALS may arise from at least two independent genotype- and protein-specific routes converging on the same vascular endpoint.
The mechanistic pathway linking TDP-43 to vascular inflammation runs through nuclear factor kappa B (NF-κB) signaling. TDP-43 is a critical governor of transcriptional output from nuclear p65/NF-κB, a transcription factor with paradoxical roles in the vasculature: it is required for basal endothelial barrier maintenance at physiological activity levels, yet drives barrier-compromising inflammatory gene programs when chronically hyperactivated [105]. Loss of normal TDP-43 regulation over this pathway, as occurs in ALS, may therefore tip endothelial NF-κB signaling from a barrier-protective to a barrier-compromising state, providing a direct molecular link between the TDP-43 proteinopathy at the core of ALS pathogenesis and the NF-κB-driven vascular permeability changes described in Section 4.7.2.
Direct evidence of TDP-43 vasculopathy comes from human autopsy material: phosphorylated TDP-43 deposits have been identified in association with small blood vessels of the spinal cord and frontal cortex in approximately half of sporadic ALS and FTLD-TDP autopsy cases examined, indicating that the protein deposits directly within the vascular compartment rather than being confined to neurons and glia [106]. This vascular wall deposition raises the possibility that TDP-43 aggregation contributes mechanically to vessel stiffening and impaired vasoreactivity, independent of its better-characterized effects on tight junction proteins.
TDP-43 dysregulation is itself induced by cerebral ischemia, as introduced in Section 4.11.2: age-related deregulation of TDP-43 after stroke enhances NF-κB-mediated inflammation and neuronal damage in the peri-infarct zone [95]. Taken together with the cerebral-ischemia-induced TDP-43 aggregation described in Section 4.3 above [20], these findings indicate a bidirectional relationship in which TDP-43 pathology both predisposes to vascular injury and is itself amplified by ischemic insult, a feed-forward loop that may be clinically relevant whenever ALS and cerebrovascular disease coexist in the same patient.

5. Stroke Mimics and Diagnostic Challenges

The differential diagnosis between ALS and acute cerebrovascular disease represents one of the most clinically consequential diagnostic challenges at their interface, with important implications for initial management, treatment decisions, and long-term care planning. The potential for diagnostic confusion is substantial, operating in both directions: ALS presentations can mimic stroke, while stroke can unmask or accelerate ALS-related deficits, and the two conditions can coexist.
Upper motor neuron–predominant ALS most commonly generates diagnostic confusion with ischemic stroke. Patients may present with subacute onset of asymmetric limb weakness, hemiparesis, or unilateral hyperreflexia and extensor plantar responses, which, in the absence of sensory deficits or cortical signs, may prompt initial evaluation along an acute stroke pathway. Bulbar-onset ALS may be mistaken for brainstem stroke or transient ischemic attack, particularly when the onset is perceived by the patient as relatively rapid [107].
Several clinical features help distinguish ALS from stroke. ALS characteristically follows a progressive, unremitting course without the abrupt symptom onset and subsequent stabilization or partial recovery typical of ischemic stroke. Fasciculations on neurological examination are pathognomonic of motor neuron disease and are not a feature of cerebrovascular disease. Bilateral motor signs or widespread hypereflexia without corresponding bilateral neuroimaging lesions should raise suspicion for a diffuse upper motor neuron disorder such as ALS or primary lateral sclerosis. The absence of sensory deficits in the context of significant motor weakness is also more consistent with motor neuron disease than with most stroke subtypes, in which somatosensory pathways are typically involved [16,108].
Neuroimaging is essential but requires careful interpretation. DWI-MRI sequences are the gold standard for detection of acute ischemia and should be obtained urgently in all patients presenting with acute neurological deficits to exclude embolic or thrombotic stroke before entertaining a neurodegenerative diagnosis. In ALS, structural T1-weighted MRI may demonstrate motor cortex atrophy and signal change in the corticospinal tracts on T2/FLAIR sequences, while resting-state fMRI reveals decreased functional connectivity within the sensorimotor network [109]. These findings are diagnostically valuable but require interpretation by neurologists experienced in both stroke and neurodegenerative disease.
EMG is indispensable in establishing lower motor neuron involvement as a diagnostic criterion under both El Escorial [108] and Awaji-Shima criteria and cannot be substituted by any imaging modality. Active denervation (fibrillations, positive sharp waves) and chronic reinnervation patterns on EMG, particularly when distributed across multiple body regions, are highly suggestive of ALS and effectively exclude most stroke etiologies.
This electrodiagnostic confirmation is, however, far from universally accessible. EMG remains severely under-resourced across sub-Saharan Africa and many other low- and middle-income country (LMIC) regions, with knowledge of the test and its diagnostic role limited among both patients and primary care providers, and electrodiagnostic services, where available, concentrated in tertiary urban centers inaccessible to rural populations [110,111]. The practical consequence is that diagnosis in many LMIC settings frequently rests on clinical assessment alone, a standard that is insufficient for atypical presentations, patients with concurrent vascular pathology, or early-stage disease without clear fasciculations or widespread LMN signs, and that compounds the stroke-mimicry challenges described throughout this section. Section 8 discusses the implications of this resource gap in greater depth.
The coexistence of ALS and stroke substantially compounds diagnostic complexity. An ALS patient experiencing a new ischemic stroke may present with acute worsening of pre-existing motor deficits rather than the classic sudden-onset stroke syndrome, as the new vascular lesion may augment deficits already present from neurodegeneration. Conversely, upper motor neuron changes from a small cortical or subcortical infarct may be misattributed to ALS progression in a patient with established disease. In such cases, DWI-MRI is essential to identify new ischemic lesions, and changes in the rate of ALSFRS-R decline may help distinguish disease progression from new vascular events.

Biomarkers in the Differential Diagnosis of ALS and Stroke

Circulating biomarkers offer a complementary and increasingly accessible avenue for resolving diagnostic uncertainty at the ALS–stroke interface, particularly in settings where the gold-standard tools discussed above are unavailable or inconclusive.
Neurofilament light chain (NfL), discussed later in this review as a prognostic and vascular-risk marker in ALS (Section 9, Future Research Directions), is also informative diagnostically. Plasma and CSF NfL concentrations are characteristically and substantially elevated in ALS, reflecting ongoing axonal degeneration, whereas NfL elevation after ischemic stroke is typically more modest in magnitude and follows a self-limited time course that parallels infarct evolution and subsequent resolution rather than the sustained, progressively rising trajectory seen in ALS [112]. Serial NfL measurement, rather than a single value, may therefore help distinguish a stable or resolving vascular insult from ongoing neurodegeneration in diagnostically ambiguous presentations.
Glial fibrillary acidic protein (GFAP) adds discriminative value as a marker of astrocytic injury and BBB disruption [113]. GFAP rises acutely and substantially after large-vessel ischemic and hemorrhagic stroke, reflecting astrocytic and glial injury at the infarct site, whereas its elevation in ALS is comparatively modest and reflects the chronic, low-grade astrogliosis described in Section 4.7 rather than an acute glial injury response [114]. A high GFAP-to-NfL ratio, or a GFAP elevation that is disproportionate to the degree of NfL elevation, may therefore favor an acute vascular over a neurodegenerative process, although prospective validation of any such ratio specifically in the ALS–stroke differential remains to be performed.
Combined biomarker panels are likely to outperform any single analyte. Panels integrating NfL with GFAP, the albumin quotient, or other markers of BBB integrity (Section 4.10), and inflammatory markers such as C-reactive protein and IL-6 (Section 4.7.2) have shown improved discriminative performance over single markers in other neurodegenerative-versus-vascular diagnostic contexts, and analogous panel-based approaches warrant prospective evaluation specifically for the ALS–stroke differential [112,114].
Several considerations temper enthusiasm for biomarker-based differentiation at present. Concurrent cerebrovascular disease in a patient with established ALS, the very population in whom diagnostic clarity is most needed, confounds the specificity of NfL and GFAP for either process individually, since both conditions may elevate the same analytes simultaneously. Reference ranges and cutoffs for these markers have been derived predominantly from single-disease cohorts rather than from patients with suspected or confirmed dual pathology, limiting their direct applicability to the diagnostic scenarios of greatest clinical relevance to this review. Also, assay availability, cost, and turnaround time remain substantial barriers in the resource-limited settings discussed in Section 8, potentially restricting biomarker-based diagnostic pathways to well-resourced tertiary centers even as they are validated. Prospective studies enrolling patients with diagnostically ambiguous presentations at the ALS–stroke interface, rather than patients with already-confirmed single diagnoses, are needed to establish the real-world incremental value of these biomarkers over clinical assessment, neuroimaging, and EMG alone.

6. Clinical Management Implications

The concurrent presence of ALS and cerebrovascular disease creates clinical management challenges of exceptional complexity, spanning acute neurological emergencies, chronic vascular risk factor management, supportive care optimization, and ethically nuanced end-of-life decision-making. An integrated, multidisciplinary approach is required across all of these domains. Table 2 summarizes key management considerations and recommended approaches for each clinical domain.
Table 2. Clinical Management Considerations in Patients with Concurrent ALS and Cerebrovascular Disease.
Timely diagnostic workup is itself a management priority, since delay carries direct clinical consequences for patients at the ALS–CVD interface. Diagnostic delay in ALS is a global phenomenon, with median time from symptom onset to diagnosis ranging from several months to over one year even in well-resourced settings [116,117], and substantially longer where specialist neurology and electrodiagnostic services are scarce, as discussed further in Section 8. These delays are clinically harmful: they postpone patient counseling and prognostication, defer initiation of supportive interventions and riluzole, and exclude patients from potential clinical trial participation [118]. In the context of concurrent cerebrovascular disease, diagnostic delay is particularly consequential because early misclassification as stroke, discussed in Section 5 above, may result in inappropriate anticoagulation or antiplatelet therapy administered without recognition of ALS-related bleeding risk or dysphagia, underscoring why the workup principles in Table 2 above should be applied as early as possible in the diagnostic pathway.
Anticoagulation and antiplatelet management in patients with both ALS and cerebrovascular disease demands individualized risk-benefit assessment. ALS-related immobility confers significant VTE risk [31], necessitating pharmacological prophylaxis, yet dysphagia may compromise oral administration of antiplatelet or anticoagulant agents. In patients who experience acute ischemic stroke, the decision to administer IV thrombolysis or pursue endovascular thrombectomy must account for pre-existing functional status, rate of ALS progression, respiratory reserve (FVC), and patient-expressed preferences—all within a compressed time window. No evidence-based guidelines specifically address thrombolysis in ALS patients, underscoring an urgent clinical evidence gap.
Respiratory management is a central and often rate-limiting consideration in ALS-CVD co-management. ALS-related FVC decline constrains post-stroke rehabilitation capacity, creates aspiration pneumonia risk from neurogenic dysphagia, and may alter the risk-benefit calculus for invasive stroke interventions. FVC should be measured at baseline and at regular intervals, with NIV initiated according to established ALS management guidelines. Respiratory involvement should be explicitly communicated to the stroke team when managing acute cerebrovascular events in ALS patients.
Systematic vascular risk factor control is clinically actionable and may have dual benefit in patients with ALS and cerebrovascular disease by reducing the risk of recurrent vascular events and potentially limiting microvascular injury to the motor cortex [115]. These interventions should be integrated into regular ALS multidisciplinary clinic visits rather than managed separately in cardiology or primary care settings to ensure coherent and coordinated care.
Nutritional assessment and support require particular attention, given the high prevalence of malnutrition in ALS [32] and the additional nutritional demands imposed by stroke recovery. Early dietitian involvement, calorically dense supplementation, and timely consideration of percutaneous endoscopic gastrostomy (PEG), ideally while FVC remains above 50%, are important elements of proactive nutritional management. Oral feeding strategies must account for both ALS-related and post-stroke neurogenic dysphagia, which may compound each other unpredictably.
Advance care planning is an ethical imperative in this population and should be initiated early, well before acute events render it urgent. Patients with ALS should be engaged in structured discussions about their goals of care, resuscitation preferences, ventilatory wishes, and decision-making for acute neurological emergencies. The occurrence of acute stroke in a patient with established ALS raises particularly difficult questions about the appropriateness of aggressive revascularization, ICU admission, and long-term organ support decisions that are best made proactively in the context of a documented, patient-centered advance directive rather than under the pressure of an acute event [119].

7. Prognostic Interactions

The coexistence of cerebrovascular disease may substantially alter the natural history and clinical trajectory of ALS, though direct evidence from longitudinal studies specifically designed to capture this interaction remains limited. Converging data from multiple indirect sources, however, support clinically meaningful prognostic interactions between the two conditions.
ALS prognosis is governed by a constellation of factors, including site of onset, rate of functional decline, degree of respiratory and bulbar involvement, cognitive status, and diagnostic delay [119,120]. Cerebrovascular disease may adversely modify each of these prognostic domains. Focal brain injury from ischemic stroke adds to the motor deficit burden in a system already compromised by ongoing neurodegeneration, and the post-stroke inflammatory response may accelerate ALS-relevant neuronal injury mechanisms in peri-infarct motor regions [16,121]. White matter hyperintensities and microvascular damage associated with chronic cerebrovascular disease disrupt corticospinal tract and motor network connectivity, potentially worsening both UMN and LMN clinical expression and accelerating ALSFRS-R decline.
Direct evidence that stroke shortens ALS survival comes from the Catalan registry data, where a prior history of stroke was associated with significantly reduced survival from ALS diagnosis [14]. Reduced microvascular integrity within the motor cortex, as characterized by Schreiber et al. using high-resolution MRI, has been independently associated with ALS clinical parameters, suggesting that vascular health of the motor cortex is a pathophysiologically relevant determinant of disease severity and progression [115]. Conversely, epidemiological evidence confirms that prior cerebrovascular injury modestly but significantly elevates subsequent ALS risk, consistent with a model in which vascular insults lower the neurodegenerative threshold in susceptible individuals [7].
The therapeutic implications of these prognostic interactions are important. Riluzole treatment and regular attendance at specialized multidisciplinary ALS clinics are the two interventions most consistently associated with improved ALS survival in clinical studies [122]. Integrating cerebrovascular risk factor management within this multidisciplinary framework represents a clinically actionable strategy for attenuating the prognostic impact of vascular comorbidity on ALS outcomes. Whether such integrated management translates into measurable improvements in ALSFRS-R trajectory or survival requires a prospective study.

8. Implications for Low- and Middle-Income Countries

ALS poses disproportionate and largely unmet diagnostic, management, and research challenges in low- and middle-income countries (LMICs), where the intersection with cerebrovascular disease creates compounded clinical complexity in settings with restricted resources [111]. Sub-Saharan Africa, which represents the most data-sparse LMIC region for ALS, illustrates the challenges common to many LMICs: severely restricted access to specialist neurology, limited availability of multidisciplinary ALS care, inconsistent access to disease-modifying therapy with riluzole, and predominance of healthcare resources directed toward infectious and mother–-child health burdens [123,124].
A critical clinical challenge unique to LMICs is the systematic early misclassification of ALS as cerebrovascular disease [107]. The motor presentations of ALS closely overlap with stroke phenomenology, particularly brainstem or lacunar infarct. In LMIC settings where neuroimaging is inaccessible, where population rates of hypertension and other vascular risk factors are high, and where neurological specialist assessment is unavailable at the point of initial contact, these presentations are frequently and understandably attributed to stroke. This misclassification initiates management along an inappropriate stroke pathway while the underlying progressive neurodegeneration remains unrecognized and untreated [107,125].
Health systems in LMICs are predominantly oriented toward high-burden infectious diseases and mother–child health, with rare neurological disorders receiving minimal resource allocation [126]. ALS research in sub-Saharan Africa relies heavily on external funding and international collaborations, which, while valuable for accessing expertise and resources [127], may not consistently align with locally identified research priorities or community-relevant outcomes. Ethical challenges are compounded in LMIC research contexts: variable health literacy, cultural beliefs about chronic progressive neurological illness, concerns about genetic testing and family implications, and variable regulatory frameworks all require culturally sensitive approaches to research engagement and informed consent.
Strengthening LMIC capacity for ALS diagnosis and care at the ALS-CVD interface requires a multi-pronged strategy: training programs for primary care physicians in clinical recognition of ALS red flags and differentiation from stroke; expansion of electrodiagnostic services beyond tertiary centers; development of low-cost, validated clinical diagnostic tools adapted to LMIC contexts; linkage of neurological disease registries with stroke and cardiovascular databases; and investment in locally led research programs with sustainable infrastructure for longitudinal data collection.

9. Future Research Directions

The evidence synthesized in this review makes clear that the ALS-cerebrovascular interface is clinically important but poorly characterized. A focused, multi-level research agenda is needed to move from observational associations to mechanistic understanding and clinically actionable insights.
Prospective longitudinal cohort studies represent the most urgent methodological priority. The available evidence base is dominated by retrospective registry analyses and cross-sectional studies that cannot establish temporality or causality. Prospective cohorts that systematically enroll ALS patients from diagnosis and follow them longitudinally, capturing incident vascular events, vascular risk factor trajectories, imaging biomarkers, and functional outcomes, are essential for determining whether cerebrovascular comorbidity independently accelerates ALS progression or merely reflects shared underlying biology. Such cohorts should incorporate structured vascular phenotyping, including blood pressure monitoring, fasting lipid and glucose profiles, ECG, echocardiography, and brain MRI with white matter hyperintensity quantification.
Neuroimaging presents important opportunities to characterize vascular contributions to ALS that are currently invisible to conventional structural MRI. Advanced techniques including quantitative perfusion MRI (ASL), dynamic contrast-enhanced MRI for BBB permeability mapping, vessel wall MRI for intracranial atherosclerosis characterization, and high-resolution resting-state fMRI for NVC quantification offer the potential to identify vascular biomarkers of disease severity and progression in ALS. Presymptomatic BBB permeability, detectable by radiotracer imaging in animal models before motor neuron loss, should be systematically evaluated in familial ALS cohorts with known genetic risk to determine whether vascular changes precede clinical onset and could serve as early biomarkers.
Blood-based biomarkers represent another high-priority area. Given the protracted pre-diagnostic interval in ALS averaging one year or more from symptom onset to confirmed diagnosis, circulating markers of BBB disruption (serum GFAP, NfL, albumin quotient, claudin-5), endothelial activation (ICAM-1, VCAM-1, E-selectin), and neuroinflammation (TNF-α, IL-6, IL-1β, CRP) should be prospectively evaluated for their ability to stratify vascular risk and predict neurological outcomes in ALS populations. Plasma NfL, already established as a prognostic biomarker in ALS, may also reflect concurrent vascular injury, confounding its specificity for neurodegeneration.
Registry linkage at national and international scales is essential for generating the sample sizes required to characterize rare events and interactions. Linking the National ALS Registry with stroke, cardiac, and vascular comorbidity databases would enable population-level analyses examining stroke type, timing, laterality, and mechanism relative to ALS onset, phenotype, and progression. International collaboration is needed to determine whether the ALS-CVD association varies by population, geography, or genetic background. These analyses would also allow evaluation of medication effects, including antiplatelet agents, statins, and antihypertensives, on ALS outcomes.
Therapeutic implications of the ALS-CVD overlap should be explored in dedicated clinical studies. The mechanistic convergence through glutamate excitotoxicity, BBB dysfunction, and NF-κB-mediated neuroinflammation raises the possibility that interventions targeting these shared pathways could benefit both conditions simultaneously. Similarly, whether aggressive vascular risk factor control in ALS patients modifies ALSFRS-R trajectory or survival should be formally tested in a randomized or quasi-experimental study design.
LMIC-specific research must be explicitly funded and prioritized, not treated as a secondary consideration. Locally led studies that characterize the burden of misdiagnosis, assess the feasibility of low-cost diagnostic pathways, and evaluate culturally adapted interventions for patients with ALS-CVD overlap in resource-limited settings are essential for global equity in neurological care.

Multi-Omics Approaches

Multi-omics approaches integrating genomics, transcriptomics, proteomics, and metabolomics offer a complementary and increasingly feasible strategy for resolving the shared and divergent pathways that connect ALS and cerebrovascular disease [128,129]. Rather than testing single candidate genes or proteins in isolation, multi-omics frameworks allow unbiased, hypothesis-generating characterization of pathway-level convergence across both conditions simultaneously.
Genomic approaches, including genome-wide association studies and polygenic risk scoring, could clarify whether ALS-associated risk variants, beyond the well-characterized monogenic causes discussed in the Introduction and Section 4.12, contribute more broadly to cerebrovascular vulnerability, and conversely whether established stroke risk loci modify ALS susceptibility or phenotype [130]. Transcriptomic and single-cell RNA sequencing studies of vascular and perivascular cell populations in ALS tissue could extend the bulk-tissue and animal-model findings summarized throughout Section 4 by resolving which specific endothelial, pericyte, or astrocytic subpopulations drive the BBB and neurovascular coupling abnormalities described there [131,132]. Proteomic profiling of plasma, CSF, and vascular tissue could identify novel shared protein signatures beyond the candidate markers (NfL, GFAP, TDP-43, SOD1) already discussed in this review, while metabolomic approaches could extend the lipid and carnitine metabolism findings noted in Section 4.3 to a more comprehensive, unbiased characterization of the metabolic intersection between the two diseases.
The principal value of multi-omics integration lies in cross-layer analysis: combining genomic, transcriptomic, proteomic, and metabolomic data within the same patients, ideally within the prospective longitudinal cohorts proposed earlier in this section, could establish whether genetic risk variants translate into specific transcriptional and protein-level vascular phenotypes, and whether these in turn predict clinical vascular events in ALS [133,134]. Such integrative analyses require large sample sizes, standardized sample collection and omics protocols, and substantial bioinformatic and computational infrastructure, and would benefit from the same registry-linkage and international-collaboration strategies described above. Given these resource requirements, multi-omics approaches to the ALS–cerebrovascular interface are likely to be feasible first in well-resourced consortia, with translation to broader and more diverse populations, including those in LMICs, as an explicit downstream priority rather than an afterthought.

10. Conclusions

ALS and cerebrovascular disease are connected at multiple levels: epidemiologically, through bidirectional associations that exceed chance; pathophysiologically, through shared mechanisms of neuroinflammation, oxidative stress, excitotoxicity, and blood–brain barrier disruption; clinically, through diagnostic confusion arising from stroke mimicry; and prognostically, through accelerated functional decline when the two conditions co-occur. The central message of this review is that these two diseases cannot be fully understood or optimally managed in clinical isolation from one another.
The key findings of this review can be summarized as follows. First, ALS patients face an approximately 2.6-fold elevated risk of ischemic stroke compared with matched controls, and prior cerebrovascular injury modestly increases subsequent ALS risk, together establishing a clinically significant bidirectional epidemiological relationship [5,6,7]. Second, multiple converging molecular pathways, including microglial M1 polarization, NF-κB-driven cytokine cascades, SOD1- and TDP-43-mediated oxidative injury, glutamate receptor overactivation, and BBB tight junction disruption, provide a biologically plausible and mechanistically rich basis for the observed clinical overlap. Third, diagnostic mimicry of stroke by upper motor neuron–predominant ALS represents an under-recognized source of misdiagnosis and mismanagement, particularly in resource-limited settings where EMG and neuroimaging are unavailable. Fourth, concurrent cerebrovascular disease appears to accelerate functional decline and shorten survival in ALS, creating an urgency for proactive vascular risk management integrated into ALS multidisciplinary care. Fifth, LMICs bear a disproportionate diagnostic and research burden that requires targeted, locally driven solutions.
The path forward requires a fundamental reorientation of research design: from single-disease retrospective studies to prospective, longitudinal, registry-linked investigations that capture both ALS and cerebrovascular disease within the same patient population. It also requires clinical innovation, integrated ALS-vascular clinics, structured advanced care planning, and evidence-based protocols for managing acute cerebrovascular events in ALS and global equity systematic investment in LMIC diagnostic and research capacity. With these commitments, the ALS-cerebrovascular interface can move from a recognized but neglected clinical challenge to an area of active, productive, and ultimately patient-benefiting inquiry.

Author Contributions

N.A. conceptualised the study; N.A., E.C.M., A.A.H., R.M.K., W.T., H.K.A., A.J., O.E.A., M.P.O., and E.O.E. were involved in the literature review; N.A. and R.M.K. extracted the data from the reviewed studies; N.A., E.C.M., A.A.H., R.M.K., W.T., H.K.A., A.J., O.E.A., M.P.O., and E.O.E. wrote the first and final drafts. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Conflicts of Interest

The authors declare that they have no competing interests.

Abbreviations

ALS—amyotrophic lateral sclerosis; ALS-FTD—amyotrophic lateral sclerosis–frontotemporal dementia; ALSFRS-R—ALS Functional Rating Scale–Revised; apoA1—apolipoprotein A1; BBB—blood–brain barrier; BP—blood pressure; BSCB—blood–spinal cord barrier; C9orf72—chromosome 9 open reading frame 72; CCL2—chemokine (C-C motif) ligand 2; CHD—coronary heart disease; CNS—central nervous system; CRP—C-reactive protein; CSF—cerebrospinal fluid; CVD—cerebrovascular disease; DWI—diffusion-weighted imaging; EAAT2/GLT-1—excitatory amino acid transporter 2; ECG—electrocardiogram; EMG—electromyography; eNMDAR—extrasynaptic N-methyl-D-aspartate receptor; EPO—erythropoietin; fALS—familial amyotrophic lateral sclerosis; FLAIR—fluid-attenuated inversion recovery; fMRI—functional magnetic resonance imaging; FUS—fused in sarcoma; FVC—forced vital capacity; GFAP—glial fibrillary acidic protein; HDL—high-density lipoprotein; HIF-1α—hypoxia-inducible factor 1-alpha; ICAM-1—intercellular adhesion molecule 1; IgG—immunoglobulin G; IL—interleukin; IV—intravenous; LMIC—low- and middle-income country; LMN—lower motor neuron; MHC—major histocompatibility complex; MMP—matrix metalloproteinase; MRI—magnetic resonance imaging; NADPH—nicotinamide adenine dinucleotide phosphate; NF-κB—nuclear factor kappa B; NfL—neurofilament light chain; NIV—non-invasive ventilation; NMDA—N-methyl-D-aspartate; NMDAR—N-methyl-D-aspartate receptor; NO—nitric oxide; NVU—neurovascular unit; NVC—neurovascular coupling; pTDP-43—phosphorylated TAR DNA-binding protein 43; PEG—percutaneous endoscopic gastrostomy; PHD-2—prolyl hydroxylase domain protein 2; ROS—reactive oxygen species; sALS—sporadic amyotrophic lateral sclerosis; SANRA—Scale for the Assessment of Narrative Review Articles; sNMDAR—synaptic N-methyl-D-aspartate receptor; SOD1—superoxide dismutase 1; TARDBP—TAR DNA-binding protein gene; TDP-43—TAR DNA-binding protein 43; TIA—transient ischemic attack; TNF-α—tumor necrosis factor alpha; TRPM4—transient receptor potential melastatin 4; UMN—upper motor neuron; VCAM-1—vascular cell adhesion molecule 1; VEGF—vascular endothelial growth factor; VEGFR—vascular endothelial growth factor receptor; VTE—venous thromboembolism; QAlb—albumin quotient.

References

  1. Brown, R.H., Jr.; Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017, 377, 162–172. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Bjelica, B.; Bartels, M.B.; Hesebeck-Brinckmann, J.; Petri, S. Non-motor symptoms in patients with amyotrophic lateral sclerosis: Current state and future directions. J. Neurol. 2024, 271, 3953–3977. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Chowdhury, A.; Mukherjee, A.; Sinharoy, U.; Pandit, A.; Biswas, A. Non-Motor Features of Amyotrophic Lateral Sclerosis: A Clinic-based Study. Ann. Indian Acad. Neurol. 2021, 24, 745–753. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Feigin, V.L.; Stark, B.A.; Johnson, C.O.; Roth, G.A.; Bisignano, C.; Abady, G.G.; Abbasifard, M.; Abbasi-Kangevari, M.; Abd-Allah, F.; Abedi, V.; et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021, 20, 795–820. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Kwon, S.; Kim, B.; Han, K.-D.; Jung, W.; Bin Cho, E.; Shin, D.W.; Min, J.-H. Increased risk of ischemic stroke in amyotrophic lateral sclerosis: A nationwide cohort study in South Korea. Neurol. Sci. 2025, 46, 2687–2695. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Diekmann, K.; Kuzma-Kozakiewicz, M.; Piotrkiewicz, M.; Gromicho, M.; Grosskreutz, J.; Andersen, P.M.; de Carvalho, M.; Uysal, H.; Osmanovic, A.; Schreiber-Katz, O.; et al. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J. Neurol. 2020, 267, 2130–2141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Turner, M.R.; Goldacre, R.; Talbot, K.; Goldacre, M.J. Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2016, 87, 244–246. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Mehta, P.; Raymond, J.; Nair, T.; Han, M.; Berry, J.; Punjani, R.; Larson, T.; Mohidul, S.; Horton, D.K. Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the National ALS Registry. Amyotroph. Lateral Scler. Front. Degener. 2025, 26, 290–295. [Google Scholar] [CrossRef] [Scilit]
  9. Target, A.L.S. Epidemiology of ALS: Incidence, Prevalence, and Suspected Clusters. Available online: https://targetals.org/news/epidemiology-of-als-incidence-prevalence-and-clusters/ (accessed on 7 March 2026).
  10. Kioumourtzoglou, M.-A.; Rotem, R.S.; Seals, R.M.; Gredal, O.; Hansen, J.; Weisskopf, M.G. Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study. JAMA Neurol. 2015, 72, 905–911. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Ingre, C.; Roos, P.M.; Piehl, F.; Kamel, F.; Fang, F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015, 7, 181–193. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  12. Pereira, M.; Gromicho, M.; Henriques, A.; Pronto-Laborinho, A.C.; Grosskreutz, J.; Kuźma-Kozakiewicz, M.; Petri, S.; Uysal, H.; Swash, M.; de Carvalho, M. Cardiovascular comorbidities in amyotrophic lateral sclerosis. J. Neurol. Sci. 2021, 420, 117273. [Google Scholar]
  13. Levison, L.S.; Blicher, J.U.; Andersen, H. Incidence and mortality of ALS: A 42-year population-based nationwide study. J. Neurol. 2025, 272, 44. [Google Scholar] [CrossRef] [Scilit]
  14. Bertran-Recasens, B.; Vidal-Notari, S.; Hernández Guillamet, G.; López Seguí, F.; Vidal-Alaball, J.; Jiménez-Balado, J.; Rubio, M.A. Epidemiology of amyotrophic lateral sclerosis: A population-based analysis, 2015–2020. Amyotroph. Lateral Scler. Front. Degener. 2025, 26, 784–793. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Pupillo, E.; Bianchi, E.; Leone, M.A.; Corbo, M.; Filosto, M.; Padovani, A.; Risi, B.; Vedovello, M.; dell’Era, V.; Cerri, F.; et al. Understanding Long-Term Survival in ALS: A Cohort Study on Subject Characteristics and Prognostic Factors. J. Clin. Med. 2025, 14, 7351. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Hardiman, O.; Al-Chalabi, A.; Chio, A.; Corr, E.M.; Logroscino, G.; Robberecht, W.; Shaw, P.J.; Simmons, Z.; van den Berg, L.H. Amyotrophic Lateral Sclerosis. Nat. Rev. Dis. Primers 2017, 3, 17071, Erratum in Nat. Rev. Dis. Primers 2017, 3, 17085. https://doi.org/10.1038/nrdp.2017.85. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Chourpiliadis, C.; Løvik, A.; Seitz, C.; Hu, Y.; Wu, J.; Ljungman, P.; Press, R.; Samuelsson, K.; Ingre, C.; Fang, F. Association between cardiometabolic diseases and the risk and progression of motor neuron diseases in Sweden: A population-based case–control study. Lancet Reg. Health Eur. 2024, 49, 101173. [Google Scholar] [CrossRef] [Scilit]
  18. Wang, H.; O’Reilly, É.J.; Weisskopf, M.G.; Logroscino, G.; McCullough, M.L.; Thun, M.J.; Schatzkin, A.; Kolonel, L.N.; Ascherio, A. Smoking and risk of amyotrophic lateral sclerosis: A pooled analysis of five prospective cohorts. Arch. Neurol. 2011, 68, 207–213. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Weisskopf, M.G.; Morozova, N.; O’Reilly, E.J.; McCullough, M.L.; Calle, E.E.; Thun, M.J.; Ascherio, A. Prospective study of chemical exposures and amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80, 558–561. [Google Scholar] [CrossRef] [Scilit]
  20. Kahl, A.; Blanco, I.; Jackman, K.; Baskar, J.; Milaganur Mohan, H.; Rodney-Sandy, R.; Zhang, S.; Iadecola, C.; Hochrainer, K. Cerebral ischemia induces the aggregation of proteins linked to neurodegenerative diseases. Sci. Rep. 2018, 8, 2701. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Mitroshina, E.V.; Savyuk, M.O.; Ponimaskin, E.; Vedunova, M.V. Hypoxia-Inducible Factor (HIF) in Ischemic Stroke and Neurodegenerative Disease. Front. Cell Dev. Biol. 2021, 9, 703084. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Guo, K.; Savelieff, M.G.; Jang, D.G.; Teener, S.J.; Zhao, L.; Hur, J.; Goutman, S.A.; Feldman, E.L. Longitudinal Metabolomics in Amyotrophic Lateral Sclerosis Implicates Impaired Lipid Metabolism. Ann. Neurol. 2025, 98, 19–34. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Fernández-Beltrán, L.C.; Godoy-Corchuelo, J.M.; Losa-Fontangordo, M.; Williams, D.; Matias-Guiu, J.; Corrochano, S. A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice. Int. J. Mol. Sci. 2021, 22, 9553. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Thompson, A.G.; Talbot, K.; Turner, M.R. Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2022, 93, 75–81. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Nakken, O.; Vaage, A.M.; Stigum, H.; Bjornevik, K.; Holmoy, T.; Meyer, H.E. Duration of Current Statin Use and Amyotrophic Lateral Sclerosis Risk: A Norwegian Population-Based Cohort Study. Neurology 2025, 105, e214221. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Garbuzova-Davis, S.; Woods, R.L., 3rd; Louis, M.K.; Zesiewicz, T.A.; Kuzmin-Nichols, N.; Sullivan, K.L.; Miller, A.M.; Hernandez-Ontiveros, D.G.; Sanberg, P.R. Reduction of Circulating Endothelial Cells in Peripheral Blood of ALS Patients. PLoS ONE 2010, 5, e10614. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Garbuzova-Davis, S.; Hernandez-Ontiveros, D.G.; Rodrigues, M.C.O.; Haller, E.; Frisina-Deyo, A.; Mirtyl, S.; Sallot, S.; Saporta, S.; Borlongan, C.V.; Sanberg, P.R. Impaired blood–brain/spinal cord barrier in ALS patients. Brain Res. 2012, 1469, 114–128. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Mattsson, P.; Lönnstedt, I.; Nygren, I.; Askmark, H. Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age. J. Neurol. Neurosurg. Psychiatry 2012, 83, 390–394. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Turner, M.R. Is cardiovascular fitness a risk factor for ALS? J. Neurol. Neurosurg. Psychiatry 2017, 88, 538. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Visser, A.E.; Seelen, M.; Hulsbergen, A.; de Graaf, J.; van der Kooi, A.J.; Raaphorst, J.; Veldink, J.H.; van den Berg, L.H. Exploring the fitness hypothesis in ALS: A population-based case-control study of parental cause of death and lifespan. J. Neurol. Neurosurg. Psychiatry 2017, 88, 550–556. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Gladman, M.; DeHaan, M.; Pinto, H.; Geerts, W.; Zinman, L. Venous thromboembolism in amyotrophic lateral sclerosis. Neurology 2014, 82, 1674–1677. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. D’Amico, E.; Grosso, G.; Nieves, J.W.; Zanghì, A.; Factor-Litvak, P.; Mitsumoto, H. Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients 2021, 13, 2273. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Peters, T.L.; Qiu, W.; Yang, H.; Huang, W.; Hu, Y.; Zou, Z.; Ye, W. Associations of cachexia and frailty with amyotrophic lateral sclerosis. Sci. Rep. 2025, 15, 4437. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Barkhudaryan, A.; Doehner, W.; Jauert, N. Autonomic dysfunction after stroke: An overview of recent clinical evidence and perspectives on therapeutic management. Clin. Auton. Res. 2025, 35, 553–563. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Baltadzhieva, R.; Gurevich, T.; Korczyn, A.D. Autonomic impairment in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2005, 18, 487–493. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Dubbioso, R.; Provitera, V.; Pacella, D.; Santoro, L.; Manganelli, F.; Nolano, M. Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: A prospective longitudinal cohort study. J. Neurol. 2023, 270, 4968–4977. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Blanc, C.; Zeller, M.; Cottin, Y.; Daubail, B.; Vialatte, A.L.; Giroud, M.; Béjot, Y. Takotsubo Cardiomyopathy Following Acute Cerebral Events. Eur. Neurol. 2015, 74, 163–168. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Wagner, S.; Güthe, T.; Bhogal, P.; Cimpoca, A.; Ganslandt, O.; Bäzner, H.; Henkes, H. Aneurysmal subarachnoid hemorrhage as a trigger for Takotsubo syndrome: A comprehensive review. Rev. Cardiovasc. Med. 2021, 22, 1241–1251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Finsterer, J.; Wahbi, K. CNS disease triggering Takotsubo stress cardiomyopathy. Int. J. Cardiol. 2014, 177, 322–329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Bozzoni, V.; Pansarasa, O.; Diamanti, L.; Nosari, G.; Cereda, C.; Ceroni, M. Amyotrophic lateral sclerosis and environmental factors. Funct. Neurol. 2016, 31, 7–19. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Streit, W.J.; Mrak, R.E.; Griffin, W.S.T. Microglia and neuroinflammation: A pathological perspective. J. Neuroinflammationation 2004, 1, 14. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. DiSabato, D.J.; Quan, N.; Godbout, J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016, 139, 136–153. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Komine, O.; Yamanaka, K. Neuroinflammation in motor neuron disease. Nagoya J. Med. Sci. 2015, 77, 537–549. [Google Scholar] [PubMed]
  44. Keizman, D.; Rogowski, O.; Berliner, S.; Ish-Shalom, M.; Maimon, N.; Nefussy, B.; Artamonov, I.; Drory, V.E. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009, 119, 383–389. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Lunetta, C.; Lizio, A.; Maestri, E.; Sansone, V.A.; Mora, G.; Miller, R.G.; Appel, S.H.; Chiò, A. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017, 74, 660–667. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Mehler, M.F.; Conway, S.J.; Ng, L.G.; Stanley, E.R.; et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330, 841–845. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Schulz, C.; Gomez Perdiguero, E.; Chorro, L.; Szabo-Rogers, H.; Cagnard, N.; Kierdorf, K.; Prinz, M.; Wu, B.; Jacobsen, S.E.; Pollard, J.W.; et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336, 86–90. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Ueno, M.; Fujita, Y.; Tanaka, T.; Nakamura, Y.; Kikuta, J.; Ishii, M.; Yamashita, T. Layer V cortical neurons require microglial support for survival during postnatal development. Nat. Neurosci. 2013, 16, 543–551. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Tam, W.Y.; Ma, C.H. Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes. Sci. Rep. 2014, 4, 7279. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Appel, S.H.; Zhao, W.; Beers, D.R.; Henkel, J.S. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011, 30, 4–8. [Google Scholar] [PubMed]
  51. Saijo, K.; Crotti, A.; Glass, C.K. Regulation of microglia activation and deactivation by nuclear receptors. Glia 2013, 61, 104–111. [Google Scholar] [PubMed]
  52. Hu, Y.; Cao, C.; Qin, X.Y.; Yu, Y.; Yuan, J.; Zhao, Y.; Cheng, Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017, 7, 9094. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Källstig, E.; McCabe, B.D.; Schneider, B.L. The Links between ALS and NF-κB. Int. J. Mol. Sci. 2021, 22, 3875. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Sweeney, M.D.; Zhao, Z.; Montagne, A.; Nelson, A.R.; Zlokovic, B.V. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol. Rev. 2019, 99, 21–78. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Steinruecke, M.; Lonergan, R.M.; Selvaraj, B.T.; Chandran, S.; Diaz-Castro, B.; Stavrou, M. Blood-CNS barrier dysfunction in amyotrophic lateral sclerosis: Proposed mechanisms and clinical implications. J. Cereb. Blood Flow Metab. 2023, 43, 642–654. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Rempe, R.G.; Hartz, A.M.S.; Bauer, B. Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J. Cereb. Blood Flow Metab. 2016, 36, 1481–1507. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Yu, X.; Ji, C.; Shao, A. Neurovascular Unit Dysfunction and Neurodegenerative Disorders. Front. Neurosci. 2020, 14, 334. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Rego, A.C.; Oliveira, C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: Implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2003, 28, 1563–1574. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell Longev. 2012, 2012, 428010. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  60. Patten, D.A.; Germain, M.; Kelly, M.A.; Slack, R.S. Reactive oxygen species: Stuck in the middle of neurodegeneration. J. Alzheimers Dis. 2010, 20, S357–S367. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  61. Carrera-Juliá, S.; Moreno, M.L.; Barrios, C.; de la Rubia-Ortí, J.E.; Drehmer, E. Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: A comprehensive review. Front. Physiol. 2020, 11, 63. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  62. Liu, N.; Liu, Y.; Wang, Y.; Feng, C.; Piao, M.; Liu, M. Oxidative cell death in the central nervous system: Mechanisms and therapeutic strategies. Front. Cell Dev. Biol. 2025, 13, 1562344. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Bunton-Stasyshyn, R.K.A.; Saccon, R.A.; Fratta, P.; Fisher, E.M.C. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: New and renascent themes. Neuroscientist 2015, 21, 519–529. [Google Scholar] [PubMed]
  64. Bowling, A.C.; Schulz, J.B.; Brown, R.H., Jr.; Beal, M.F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 1993, 61, 2322–2325. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O’Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Israelson, A.; Arbel, N.; Da Cruz, S.; Ilieva, H.; Yamanaka, K.; Shoshan-Barmatz, V.; Cleveland, D.W. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron 2010, 67, 575–587. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Pedrini, S.; Sau, D.; Guareschi, S.; Bogush, M.; Brown, R.H., Jr.; Naniche, N.; Kia, A.; Trotti, D.; Pasinelli, P. ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2. Hum. Mol. Genet. 2010, 19, 2974–2986. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  68. Zhong, Z.; Deane, R.; Ali, Z.; Parisi, M.; Shapovalov, Y.; O’Banion, M.K.; Stojanovic, K.; Sagare, A.; Boillee, S.; Cleveland, D.W.; et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 2008, 11, 420–422. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Liguori, F.; Alberti, F.; Amadio, S.; Angelini, D.F.; Pilesi, E.; Vitale, G.; Tesoriere, G.; Borsellino, G.; Vernì, F.; Volonté, C. Pan-neuronal expression of human mutant SOD1 in Drosophila impairs survival and motor performance, induces early neuroinflammation and chromosome aberrations. Biochim. Biophys. Acta Mol. Basis Dis. 2024, 1870, 167192. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Olney, J.W. Neurotoxicity of excitatory amino acids. In Kainic Acid as a Tool in Neurobiology; McGeer, E.G., Olney, J.W., McGeer, P.L., Eds.; Raven Press: New York, NY, USA, 1978; pp. 95–121. [Google Scholar]
  71. Doble, A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47, S233–S241. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  72. Yan, J.; Bengtson, C.P.; Buchthal, B.; Hagenston, A.M.; Bading, H. Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants. Science 2020, 370, eaay3302. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Van Den Bosch, L.; Van Damme, P.; Bogaert, E.; Robberecht, W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2006, 1762, 1068–1082. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Saini, V.; Guada, L.; Yavagal, D.R. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology 2021, 97, S6–S16. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. van Putten, M.J.A.M.; Fahlke, C.; Kafitz, K.W.; Hofmeijer, J.; Rose, C.R. Dysregulation of Astrocyte Ion Homeostasis and Its Relevance for Stroke-Induced Brain Damage. Int. J. Mol. Sci. 2021, 22, 5679. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Ludhiadch, A.; Sharma, R.; Muriki, A.; Munshi, A. Role of Calcium Homeostasis in Ischemic Stroke: A Review. CNS Neurol. Disord. Drug Targets 2022, 21, 52–61. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  77. Shen, Z.; Xiang, M.; Chen, C.; Ding, F.; Wang, Y.; Shang, C.; Xin, L.; Zhang, Y.; Cui, X. Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke. Biomed. Pharmacother. 2022, 151, 113125. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  78. Daniele, S.G.; Trummer, G.; Hossmann, K.A.; Vrselja, Z.; Benk, C.; Gobeske, K.T.; Damjanovic, D.; Andrijevic, D.; Pooth, J.S.; Dellal, D.; et al. Brain vulnerability and viability after ischaemia. Nat. Rev. Neurosci. 2021, 22, 553–572. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Henkel, J.S.; Beers, D.R.; Wen, S.; Bowser, R.; Appel, S.H. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 2009, 72, 1614–1616. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  80. Mirian, A.; Moszczynski, A.; Soleimani, S.; Aubert, I.; Zinman, L.; Abrahao, A. Breached Barriers: A Scoping Review of Blood-Central Nervous System Barrier Pathology in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2022, 16, 851563. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  81. Assialioui, A.; Domínguez, R.; Ferrer, I.; Andrés-Benito, P.; Povedano, M. Elevated Cerebrospinal Fluid Proteins and Albumin Determine a Poor Prognosis for Spinal Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2022, 23, 11063. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  82. Hwang, D.W.; Ser, J.; Ziabrev, K.; Park, G.K.; Jo, M.J.; Yokomizo, S.; Bao, K.; Yamashita, A.; Cho, H.; Henary, M.; et al. Image-Guided Monitoring of Mitochondria and Blood-Brain Barrier Dysfunction in Amyotrophic Lateral Sclerosis Mice. Biomater. Res. 2025, 29, 0162. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  83. Cheemala, A.; Kimble, A.L.; Tyburski, J.D.; Leclair, N.K.; Zuberi, A.R.; Murphy, M.; Jellison, E.R.; Reese, B.; Hu, X.; Lutz, C.M.; et al. Loss of Endothelial TDP-43 Leads to Blood Brain Barrier Defects in Mouse Models of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. bioRxiv 2023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Pan, Y.; Spiteri, A.G.; Runwal, P.; Sun, J.; Hutchinson, D.S.; Kagawa, Y.; Turner, B.J.; Huang, C.; Shah, A.D.; Schittenhelm, R.B.; et al. Increased ATP production and P-glycoprotein activity underlie the marked changes in blood-brain barrier transport of drugs in a mouse model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 2026, 183, 280–295. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Daneman, R.; Prat, A. The Blood–Brain Barrier. Cold Spring Harb. Perspect. Biol. 2015, 7, a020412. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  86. Knowland, D.; Arac, A.; Sekiguchi, K.J.; Hsu, M.; Lutz, S.E.; Perrino, J.; Steinberg, G.K.; Barres, B.A.; Nimmerjahn, A.; Agalliu, D. Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke. Neuron 2014, 82, 603–617. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Shi, Y.; Zhang, L.; Pu, H.; Mao, L.; Hu, X.; Jiang, X.; Xu, N.; Stetler, R.A.; Zhang, F.; Liu, X.; et al. Rapid endothelial cytoskeletal reorganization enables early blood–brain barrier disruption and long-term ischaemic reperfusion brain injury. Nat. Commun. 2016, 7, 10523. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Jiang, X.; Andjelkovic, A.V.; Zhu, L.; Yang, T.; Bennett, M.V.L.; Chen, J.; Keep, R.F.; Shi, Y. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog. Neurobiol. 2018, 163–164, 144–171. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Yassin, L.K.; Skrabulyte-Barbulescu, J.; Alshamsi, S.H.; Saeed, S.; Alkuwaiti, S.H.; Almazrouei, S.; Alnuaimi, A.; BaniYas, S.; Aldhaheri, D.; Alderei, M.; et al. The microbiota–gut–brain axis in mental and neurodegenerative disorders: Opportunities for prevention and intervention. Front. Aging Neurosci. 2025, 17, 1667448. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Nagara, Y.; Tateishi, T.; Yamasaki, R.; Hayashi, S.; Kawamura, M.; Kikuchi, H.; Iinuma, K.M.; Tanaka, M.; Iwaki, T.; Matsushita, T.; et al. Impaired Cytoplasmic–Nuclear Transport of Hypoxia-Inducible Factor-1alpha in Amyotrophic Lateral Sclerosis. Brain Pathol. 2013, 23, 534–546. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Moreau, C.; Gosset, P.; Kluza, J.; Brunaud-Danel, V.; Lassalle, P.; Marchetti, P.; Defebvre, L.; Destée, A.; Devos, D. Deregulation of the hypoxia inducible factor-1alpha pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience 2011, 172, 110–117. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Arhart, R.W. A possible haemodynamic mechanism for amyotrophic lateral sclerosis. Med. Hypotheses 2010, 75, 341–346. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  93. Zamudio, F.; Loon, A.R.; Smeltzer, S.; Benyamine, K.; Navalpur Shanmugam, N.K.; Stewart, N.J.F.; Lee, D.C.; Nash, K.; Selenica, M.B. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model. J. Neuroinflammation 2020, 17, 283. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Burrell, J.R.; Halliday, G.M.; Kril, J.J.; Ittner, L.M.; Götz, J.; Kiernan, M.C.; Hodges, J.R. The frontotemporal dementia-motor neuron disease continuum. Lancet 2016, 388, 919–931. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Thammisetty, S.S.; Pedragosa, J.; Weng, Y.C.; Calon, F.; Planas, A.; Kriz, J. Age-related deregulation of TDP-43 after stroke enhances NF-kappaB-mediated inflammation and neuronal damage. J. Neuroinflammation 2018, 15, 312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Trojsi, F.; Canna, A.; Sharbafshaaer, M.; di Nardo, F.; Canale, F.; Passaniti, C.; Pirozzi, M.A.; Silvestro, M.; Orologio, I.; Russo, A.; et al. Brain neurovascular coupling in amyotrophic lateral sclerosis: Correlations with disease progression and cognitive impairment. Eur. J. Neurol. 2025, 32, e16540. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  97. Iadecola, C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron 2017, 96, 17–42. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Xu, L.; Shan, D.; Wu, D. Infarct volume as a predictor and therapeutic target in post-stroke cognitive impairment. Front. Med. 2025, 12, 1519538. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  99. Lahariya, R.; Sinha, M.; Kumari, B.; Subramanian, K.V.; Anand, G. Time-dependent neurovascular unit dysfunction in ischemic stroke: Mechanisms of neurovascular uncoupling and its clinical impact. Int. J. Neurosci. 2026, 136, 733–744. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  100. Smeyers, J.; Banchi, E.G.; Latouche, M. C9ORF72: What It Is, What It Does, and Why It Matters. Front. Cell. Neurosci. 2021, 15, 661447. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  101. Aragón-González, A.; Shaw, A.C.; Kok, J.R.; Roussel, F.S.; Santos Souza, C.D.; Granger, S.M.; Vetter, T.; de Diego, Y.; Meyer, K.C.; Beal, S.N.; et al. C9ORF72 patient-derived endothelial cells drive blood-brain barrier disruption and contribute to neurotoxicity. Fluids Barriers CNS 2024, 21, 34. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  102. Cooper-Knock, J.; Shaw, P.J.; Kirby, J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 2014, 127, 333–345. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  103. Ji, A.L.; Zhang, X.; Chen, W.W.; Huang, W.J. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. J. Med. Genet. 2017, 54, 145–154. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  104. Xiang, Y.; Gu, Q.; Liu, D. Brain Endothelial Cells in Blood-Brain Barrier Regulation and Neurological Therapy. Int. J. Mol. Sci. 2025, 26, 5843. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  105. Zhao, W.; Beers, D.R.; Bell, S.; Wang, J.; Wen, S.; Baloh, R.H.; Appel, S.H. TDP-43 activates microglia through NF-κB and NLRP3 inflammasome. Exp. Neurol. 2015, 273, 24–35. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  106. Ferrer, I.; Andrés-Benito, P.; Carmona, M.; Assialioui, A.; Povedano, M. TDP-43 Vasculopathy in the Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis (sALS) and Frontal Cortex in sALS/FTLD-TDP. J. Neuropathol. Exp. Neurol. 2021, 80, 229–239. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  107. Campanari, M.L.; Bourefis, A.R.; Kabashi, E. Diagnostic challenge and neuromuscular junction contribution to ALS pathogenesis. Front. Neurol. 2019, 10, 68. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  108. Brooks, B.R.; Miller, R.G.; Swash, M.; Munsat, T.L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000, 1, 293–299. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  109. Chiò, A.; Pagani, M.; Agosta, F.; Calvo, A.; Cistaro, A.; Filippi, M. Neuroimaging in amyotrophic lateral sclerosis: Insights into structural and functional changes. Lancet Neurol. 2014, 13, 1228–1240. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  110. Adebayo, P.B.; Taiwo, F.T.; Ogunremi, O.A.; Owolabi, M.O. Knowledge of electromyography (EMG) among sub-Saharan African patients: A pilot survey. Ann. Med. Health Sci. Res. 2018, 8, 69–73. [Google Scholar]
  111. Aderinto, N.; Muili AbdulBasit, O.; Afolayan, O.; Jolayemi, M.M. Current status and future directions of amyotrophic lateral sclerosis research in Africa: A perspective. Ann. Med. Surg. 2023, 85, 3204–3208. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  112. Steinacker, P.; Feneberg, E.; Weishaupt, J.; Brettschneider, J.; Tumani, H.; Andersen, P.M.; von Arnim, C.A.; Böhm, S.; Kassubek, J.; Kubisch, C.; et al. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J. Neurol. Neurosurg. Psychiatry 2016, 87, 12–20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  113. Abdelhak, A.; Foschi, M.; Abu-Rumeileh, S.; Yue, J.K.; D’Anna, L.; Huss, A.; Oeckl, P.; Ludolph, A.C.; Kuhle, J.; Petzold, A.; et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 2022, 18, 158–172. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  114. Abu-Rumeileh, S.; Vacchiano, V.; Zenesini, C.; Polischi, B.; de Pasqua, S.; Fileccia, E.; Mammana, A.; Di Stasi, V.; Capellari, S.; Salvi, F.; et al. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. J. Neurol. 2020, 267, 1699–1708. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Schreiber, S.; Bernal, J.; Arndt, P.; Schreiber, F.; Müller, P.; Morton, L.; Braun-Dullaeus, R.C.; Valdés-Hernández, M.D.C.; Duarte, R.; Wardlaw, J.M.; et al. Brain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity. Cells 2023, 12, 957. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  116. Zarei, S.; Carr, K.; Reiley, L.; Diaz, K.; Guerra, O.; Altamirano, P.F.; Pagani, W.; Lodin, D.; Orozco, G.; Chinea, A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015, 6, 171. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  117. Gwathmey, K.G.; Corcia, P.; McDermott, C.J.; Genge, A.; Sennfält, S.; de Carvalho, M.; Ingre, C. Diagnostic delay in amyotrophic lateral sclerosis. Eur. J. Neurol. 2023, 30, 2595–2601. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  118. Berry, J.D.; Cudkowicz, M.E. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin. Investig. 2011, 1, 1375–1389. [Google Scholar] [CrossRef]
  119. Chiò, A.; Logroscino, G.; Hardiman, O.; Swingler, R.; Mitchell, D.; Beghi, E.; Traynor, B.G. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009, 10, 310–323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  120. Su, W.M.; Cheng, Y.F.; Jiang, Z.; Duan, Q.Q.; Yang, T.M.; Shang, H.F.; Chen, Y.P. Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis. EBioMedicine 2021, 74, 103732. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  121. Turner, M.R.; Kiernan, M.C.; Leigh, P.N.; Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009, 8, 94–109. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  122. Rooney, J.; Byrne, S.; Heverin, M.; Corr, B.; Elamin, M.; Staines, A.; Goldacre, B.; Hardiman, O. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995–2010. PLoS ONE 2013, 8, e74733. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  123. Kassahun Bekele, B.; Kwizera, L.; Abdul Razzak, R.; Alfadul, E.S.A.; Anand, A.; Wojtara, M.; Nazir, A.; Uwishema, O. ALS in Africa: Current knowledge and exciting opportunities for future study. Ann. Med. Surg. 2023, 85, 5827–5830. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  124. Luna, J.; Jost, J.; Diagana, M.; Ait Aissa, L.; Tazir, M.; Ali Pacha, L.; Kacem, I.; Gouider, R.; Henning, F.; Basse, A.; et al. Clinical management and disease-modifying treatment for amyotrophic lateral sclerosis in African hospital centers: The TROPALS study. Amyotroph. Lateral Scler. Front. Degener. 2022, 23, 279–283. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  125. Lekoubou, A.; Echouffo-Tcheugui, J.B.; Kengne, A.P. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: A systematic review. BMC Public Health 2014, 14, 653. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  126. Uwishema, O.; Boon, P. Bridging the Gaps: Addressing Inequities in Neurological Care for Underserved Populations. Eur. J. Neurol. 2025, 32, e70073. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  127. Bekele, B.K.; Kwizera, L.; Razzak, R.A.; Alfadul, E.S.; Anand, A.; Wojtara, M.; Nazir, A.; Uwishema, O. ALS in Africa: Current knowledge and exciting opportunities for future study—Short communication. Ann. Med. Surg. 2023, 85, 5827–5830. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  128. Goutman, S.A.; Boss, J.; Patterson, A.; Mukherjee, B.; Batterman, S.; Feldman, E.L. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2019, 90, 907–912. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  129. Nikafshan Rad, H.; Su, Z.; Trinh, A.; Hakim Newton, M.A.; Shamsani, J.; Consortium, N.A.; Karim, A.; Sattar, A. Amyotrophic lateral sclerosis diagnosis using machine learning and multi-omic data integration. Heliyon 2024, 10, e38583. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  130. van Rheenen, W.; van der Spek, R.A.A.; Bakker, M.K.; van Vugt, J.J.F.A.; Hop, P.J.; Zwamborn, R.A.J.; de Klein, N.; Westra, H.J.; Bakker, O.B.; Deelen, P.; et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 2021, 53, 1636–1648, Erratum in Nat. Genet. 2022, 54, 361. https://doi.org/10.1038/s41588-022-01020-3. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  131. Batty, G.D.; Gale, C.R. Pre-Morbid Risk Factors for Amyotrophic Lateral Sclerosis: Prospective Cohort Study. Clin. Epidemiol. 2021, 13, 941–947. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Rizea, R.E.; Corlatescu, A.D.; Costin, H.P.; Dumitru, A.; Ciurea, A.V. Understanding Amyotrophic Lateral Sclerosis: Pathophysiology, Diagnosis, and Therapeutic Advances. Int. J. Mol. Sci. 2024, 25, 9966. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  133. Rakhit, R.; Cunningham, P.; Furtos-Matei, A.; Dahan, S.; Qi, X.F.; Crow, J.P.; Cashman, N.R.; Kondejewski, L.H.; Chakrabartty, A. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J. Biol. Chem. 2002, 277, 47551–47556. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  134. Pickles, S.; Destroismaisons, L.; Peyrard, S.L.; Cadot, S.; Rouleau, G.A.; Brown, R.H., Jr.; Julien, J.P.; Arbour, N.; Vande Velde, C. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded SOD1. Hum. Mol. Genet. 2013, 22, 3947–3959. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.